Organization
Les Laboratoires Servier SAS
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Les Laboratoires Servier SAS
... TALEN gene-edited, allogeneic CAR T product candidate in ALL patients,exclusively licensed to Servier Preliminary results of the first-in-human clinical trials of UCART19 will be presented ...
... specified development and commercialization rights. Amgen has also entered an alliance with Servier for exclusive commercialization rights in Europe as well as the Commonwealth of ...
... gene-edited, allogeneic CAR T product candidate in ALL patients, exclusively licensed to Servier Preliminary results of the first-in-human clinical trials of UCART19 will be presented ...
... and continued progression of lead assets under our alliances with AstraZeneca and Servier in respiratory disease and immuno-oncology," said Stephen S. Yoder, President and CEO ...
... and continued progression of lead assets under our alliances with AstraZeneca and Servier in respiratory disease and immuno-oncology," said Stephen S. Yoder, President and CEO ...
... Servier, Pfizer Inc. (NYSE: PFE) and Cellectis (Alternext: ALCLS - Nasdaq: CLLS), today ...
... specified development and commercialization rights. Amgen has also entered an alliance with Servier for exclusive commercialization rights in Europe as well as the Commonwealth of ...
... Regulatory News: Servier, Pfizer Inc. (NYSE: PFE) and Cellectis (Paris:ALCLS)(NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), ...
... Servier and GeNeuro (Euronext Paris: CH0308403085 - GNRO) announced today post hoc analyses ...
... Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO) and Servier announced today post hoc analyses of 6-month data from the CHANGE-MS Phase2b ...
... Servier has established a 3-year strategic research alliance with Harvard University to support ...
... Servier CDMO, the contract development and manufacturing organization (CDMO) division of Servier, today ...
... patients having completed CHANGE-MS, is fully financed by and fully recharged to Servier, and as a result does not burden our income statement or cash ...
... Regulatory News: GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO) and Servier announced today that 6-month data from the CHANGE-MS Phase2b study will be ...
... specified development and commercialization rights. Amgen has also entered an alliance with Servier for exclusive commercialization rights in Europe as well as the Commonwealth of ...
... trials assessing TG4010 (lung cancer) or Pexa-Vec (liver cancer and other solid tumors)Servier, for a scientific collaboration to improve the production process for allogenic CAR-T ...
... specified development and commercialization rights. Amgen has also entered an alliance with Servier for exclusive commercialization rights in Europe as well as the Commonwealth of ...
... Servier and Institut Curie have decided to prolong their partnership in the fight ...
... Regulatory News: GeNeuro (Paris: GNRO) (Euronext Paris: CH0308403085 - GNRO) and Servier announced today 6-month results from the 12-month CHANGE-MS Phase2b study of three ...
... annual congress to be held in Barcelona from 26 to 29 August, Servier and CardioRenal will be announcing the joint development of a telemedicine tool ...
... announced through its wholly owned Swiss subsidiary, Philochem AG, a collaboration with Servier to discover new small molecule-based therapeutics using Philochem's proprietary ESAC platform and ...
... plans to advance MRG-110, a microRNA-based therapy being developed in collaboration with Servier, into clinical development next year. MRG-110, the lead product candidate under the ...
... and Transplant Association Congress in Spain. Advancing and broadening IO pipeline with Servier: Advancement of the Company's IO partnership with Servier, including progression of our ...
... Transplant Association Congress in Spain. -- Advancing and broadening IO pipeline with Servier: Advancement of the Company's IO partnership with Servier, including progression of our ...
... Transplant Association Congress in Spain. -- Advancing and broadening IO pipeline with Servier: Advancement of the Company's IO partnership with Servier, including progression of our ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤